AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2966613 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine 200 mg with alcohol (1 g/kg)
Number of subjects: 12
Study 2966613 — intervention group
Group type: COMPARATOR
Intervention: Placebo with alcohol (1 g/kg)
Number of subjects: 12
Study 29101776 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage by mothers for their premature neonates, 15-minute sessions per day for 5 days.
Number of subjects: 40
Study 29101776 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no massages.
Number of subjects: 40
Study 29101776 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage by mothers for their premature neonates
Number of subjects: 40
Study 28969615 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic internet-delivered cognitive behaviour therapy (iCBT)
Number of subjects: 0
Study 28969615 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 26289076 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction arm
Number of subjects: 190
Study 26289076 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing regimen
Number of subjects: 190
Study 23013236 — intervention group
Group type: COMPARATOR
Intervention: Odanacatib (ODN) 50 mg
Number of subjects: 44
Study 23013236 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) 2-600 mg
Number of subjects: 44
Study 23013236 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) with high-fat meal
Number of subjects: 44
Study 23013236 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) with low-fat meal
Number of subjects: 44
Study 23013236 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN)
Number of subjects: 44
Study 20653672 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (15 mg orally)
Number of subjects: 24
Study 20653672 — intervention group
Group type: COMPARATOR
Intervention: Morphine (30 mg orally)
Number of subjects: 24
Study 18360018 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1234
Study 18360018 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 1234
Study 18360018 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1234
Study 18360018 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 1234
Study 18360018 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1234
Study 20353023 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine syndrome-differentiation therapy
Number of subjects: 360
Study 20353023 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium bromide
Number of subjects: 360
Study 16270722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast, 450 mg/day (n = 33)
Number of subjects: 67
Study 16270722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained released Theo, 200 mg/day (n = 34)
Number of subjects: 67
Study 11445757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude training
Number of subjects: 20
Study 9482294 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiograph
Number of subjects: 522
Study 9482294 — intervention group
Group type: COMPARATOR
Intervention: No chest radiograph (Control)
Number of subjects: 522
Study 7843203 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (n = 27)
Number of subjects: 59
Study 7843203 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (n = 8)
Number of subjects: 59
Study 7843203 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (n = 20)
Number of subjects: 59
Study 7843203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide (n = 9)
Number of subjects: 59
Study 7843203 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 23)
Number of subjects: 59
Study 3285833 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg torasemide
Number of subjects: 66
Study 3285833 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg indapamide
Number of subjects: 66
Study 30762487 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of 100 × 10^6 ADMSCs
Number of subjects: 30
Study 30762487 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections of 100 × 10^6 ADMSCs at baseline and 6 months
Number of subjects: 30
Study 30762487 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (Control)
Number of subjects: 30
Study 29855373 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg praziquantel
Number of subjects: 381
Study 29855373 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg praziquantel
Number of subjects: 381
Study 29855373 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg praziquantel
Number of subjects: 381
Study 29855373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PSAC)
Number of subjects: 381
Study 29855373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SAC)
Number of subjects: 381
Study 29855373 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg praziquantel (SAC)
Number of subjects: 381
Study 29855373 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg praziquantel (SAC)
Number of subjects: 381
Study 29855373 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg praziquantel (SAC)
Number of subjects: 381
Study 29855373 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg praziquantel (PSAC)
Number of subjects: 381
Study 29855373 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg praziquantel (PSAC)
Number of subjects: 381
Study 26889911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily (n=58)
Number of subjects: 110
Study 26889911 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea (n=52)
Number of subjects: 110
Study 26889911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 110
Study 26889911 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea
Number of subjects: 110
Study 23756717 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment (pharmacological and cognitive behavioral therapy)
Number of subjects: 56
Study 22437554 — intervention group
Group type: EXPERIMENTAL
Intervention: α-tocopherol (50 mg/d) supplementation
Number of subjects: 2112
Study 18818960 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy (best medical management)
Number of subjects: 0
Study 18818960 — intervention group
Group type: COMPARATOR
Intervention: Intracranial-extracranial bypass surgery
Number of subjects: 0
Study 18818960 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 0
Study 18818960 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 0
Study 18818960 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved surgical and endovascular techniques
Number of subjects: 0
Study 17980274 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 351
Study 17980274 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 351
Study 15090799 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and exercise training (1 hour of aerobic and resistance training three times a week)
Number of subjects: 37
Study 15090799 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 37
Study 11805569 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (0.2% paste applied three times a day for eight weeks)
Number of subjects: 65
Study 11805569 — intervention group
Group type: COMPARATOR
Intervention: Lateral sphincterotomy (surgery)
Number of subjects: 65
Study 11805569 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 65
Study 11805569 — intervention group
Group type: COMPARATOR
Intervention: Lateral sphincterotomy
Number of subjects: 65
Study 9743817 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS, Condrosulf, IBSA, Lugano, CH) 2 x 400 mg/day
Number of subjects: 80
Study 9743817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8092558 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg once daily for 6 weeks
Number of subjects: 118
Study 8092558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 8092558 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 118
Study 8092558 — intervention group
Group type: COMPARATOR
Intervention: Loratadine and Placebo
Number of subjects: 118
Study 3396477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin plus gentamicin (CX/GM) for 48 hours
Number of subjects: 124
Study 3396477 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (CTX) for 24 hours
Number of subjects: 124
Study 29352748 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional teaching plus the e‐learning program (application on smartphone)
Number of subjects: 62
Study 29352748 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching (control group)
Number of subjects: 62
Study 27084497 — intervention group
Group type: EXPERIMENTAL
Intervention: Controller-free interactive digital rehabilitation technology
Number of subjects: 0
Study 27084497 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 0
Study 25604912 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation combined with virtual reality training
Number of subjects: 20
Study 25604912 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation combined with virtual reality training
Number of subjects: 20
Study 23089654 — intervention group
Group type: EXPERIMENTAL
Intervention: No. 3‐0 silk suture
Number of subjects: 30
Study 23089654 — intervention group
Group type: COMPARATOR
Intervention: isoamyl 2‐cyanoacrylate glue
Number of subjects: 30
Study 20508338 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and 25-hydroxy vitamin D (25-OHD) supplementation
Number of subjects: 0
Study 20508338 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation only
Number of subjects: 0
Study 18829995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated bifurcation stents
Number of subjects: 60
Study 18829995 — intervention group
Group type: COMPARATOR
Intervention: Classic bare-metal stents
Number of subjects: 60
Study 16826439 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-factor HAQ-DI scoring system
Number of subjects: 569
Study 12360461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg daily
Number of subjects: 8076
Study 12360461 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 8076
Study 12360461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 8076
Study 12360461 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 8076
Study 10328395 — intervention group
Group type: EXPERIMENTAL
Intervention: Propamidine isethionate 0.1% ophthalmic solution (Brolene) and neomycin-polymyxin B-gramicidin ophthalmic solution (Neotricin)
Number of subjects: 83
Study 8579031 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg/day)
Number of subjects: 26
Study 8579031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2022303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (30 ml containing 3.8 g EPA and 2.5 g DHA)
Number of subjects: 8
Study 7100377 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation at 0c for every .1°F increase in finger temperature
Number of subjects: 47
Study 7100377 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation at 25c for every .1°F increase in finger temperature
Number of subjects: 47
Study 7100377 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation at 50c for every .1°F increase in finger temperature
Number of subjects: 47
Study 7100377 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestion task difficulty
Number of subjects: 47
Study 7100377 — intervention group
Group type: EXPERIMENTAL
Intervention: No-suggestion task difficulty
Number of subjects: 47
Study 31144134 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-responding-hand condition
Number of subjects: 0
Study 31144134 — intervention group
Group type: COMPARATOR
Intervention: Single-responding-hand condition
Number of subjects: 0
Study 28408010 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term sequela (LTS) risk mitigation
Number of subjects: 3160
Study 28408010 — intervention group
Group type: COMPARATOR
Intervention: HbA1c improvement
Number of subjects: 3160
Study 28408010 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of treatment-related heart attack risk
Number of subjects: 3160
Study 28408010 — intervention group
Group type: COMPARATOR
Intervention: Control for treatment-related heart attack risk
Number of subjects: 3160
Study 25995282 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) snack (26 g of protein/6 g of fat per 27 g of carbohydrates)
Number of subjects: 31
Study 25995282 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) snack
Number of subjects: 31
Study 25995282 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat (HF) snack (4 g of protein/12 g of fat per 32 g of carbohydrates)
Number of subjects: 31
Study 25995282 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat (HF) snack
Number of subjects: 31
Study 25995282 — intervention group
Group type: COMPARATOR
Intervention: No Snack (NoS)
Number of subjects: 31
Study 24722445 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/d atrasentan
Number of subjects: 211
Study 24722445 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/d atrasentan
Number of subjects: 211
Study 24722445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 24722445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of atrasentan
Number of subjects: 211
Study 24722445 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan (both doses)
Number of subjects: 211
Study 22831874 — intervention group
Group type: EXPERIMENTAL
Intervention: Single, oral supplementation of 100,000 IU vitamin D3
Number of subjects: 62
Study 22831874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 22831874 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 62
Study 20297701 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacarie
Number of subjects: 37
Study 20297701 — intervention group
Group type: COMPARATOR
Intervention: Conventional drill
Number of subjects: 37
Study 17524997 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol gel at 1.25 g/day (0.75 mg/day)
Number of subjects: 120
Study 17524997 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol gel at 2.5 g/day (1.5 mg/day)
Number of subjects: 120
Study 17524997 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol gel at 5.0 g/day (3 mg/day)
Number of subjects: 120
Study 17524997 — intervention group
Group type: COMPARATOR
Intervention: Estriol 2 mg/day p.o. (control)
Number of subjects: 120
Study 15545824 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (15 mg/kg) added to the CPB priming solution (Group MP, n = 37)
Number of subjects: 74
Study 15545824 — intervention group
Group type: COMPARATOR
Intervention: No methylprednisolone added to the CPB priming (Group NS, n = 37)
Number of subjects: 74
Study 11350567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg o.d.)
Number of subjects: 21
Study 11350567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10204735 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg pethidine (P50)
Number of subjects: 40
Study 10204735 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pethidine (P100)
Number of subjects: 40
Study 10204735 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pethidine (P200)
Number of subjects: 40
Study 10204735 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine + adrenaline (PC)
Number of subjects: 40
Study 7799085 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐DTPA
Number of subjects: 17
Study 7799085 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐HMPAO
Number of subjects: 17
Study 7799085 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 17
Study 7799085 — intervention group
Group type: EXPERIMENTAL
Intervention: DLCO
Number of subjects: 17
Study 2139843 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic LNG
Number of subjects: 10
Study 2139843 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic NET
Number of subjects: 10
Study 2139843 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic LNG
Number of subjects: 10
Study 2139843 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic GSD
Number of subjects: 10
Study 2139843 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic DSG
Number of subjects: 10
Study 2139843 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic DSG
Number of subjects: 10
Study 2139843 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic CPA
Number of subjects: 10
Study 2139843 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-nortestosterone derived progestagens
Number of subjects: 10
Study 2139843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate
Number of subjects: 10
Study 2139843 — intervention group
Group type: EXPERIMENTAL
Intervention: All preparations
Number of subjects: 10
Study 7205145 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation method for radioimmunoassay results
Number of subjects: 0
Study 28983938 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizing skincare (bathing every 2 days and using lotion daily)
Number of subjects: 227
Study 28983938 — intervention group
Group type: COMPARATOR
Intervention: Daily bathing without lotion (control)
Number of subjects: 227
Study 27657522 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS/LABA combination
Number of subjects: 107
Study 27657522 — intervention group
Group type: COMPARATOR
Intervention: ICS monotherapy
Number of subjects: 107
Study 24007699 — intervention group
Group type: EXPERIMENTAL
Intervention: Apathy present
Number of subjects: 1118
Study 24007699 — intervention group
Group type: EXPERIMENTAL
Intervention: Apathy present in 73 (7.5%) of 979 older persons without depressive symptoms and cognitive impairment
Number of subjects: 1118
Study 24007699 — intervention group
Group type: EXPERIMENTAL
Intervention: Apathy present in 77 (7%) persons with cognitive impairment only
Number of subjects: 1118
Study 24007699 — intervention group
Group type: EXPERIMENTAL
Intervention: Apathy present in 51 (5%) depressed persons without cognitive impairment
Number of subjects: 1118
Study 22411098 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted learning (CAL) plus tuition/lecture
Number of subjects: 69
Study 22411098 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted learning (CAL) alone
Number of subjects: 69
Study 20487077 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' self-report of fall events
Number of subjects: 153
Study 20487077 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall events reported in participants' case notes
Number of subjects: 153
Study 20487077 — intervention group
Group type: COMPARATOR
Intervention: Falls events reported through the hospital reporting systems
Number of subjects: 153
Study 20487077 — intervention group
Group type: COMPARATOR
Intervention: Hospital reporting systems
Number of subjects: 153
Study 17320346 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD patients
Number of subjects: 0
Study 17320346 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 17320346 — intervention group
Group type: COMPARATOR
Intervention: Panic disorder patients
Number of subjects: 0
Study 15758763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) 300 mg, 3 times daily
Number of subjects: 100
Study 15758763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 14606784 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 51
Study 14606784 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 51
Study 14606784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10828647 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (copolymer 1)
Number of subjects: 299
Study 8864316 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg orally)
Number of subjects: 28
Study 8864316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8864316 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 28
Study 1632394 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst overdrive pacing
Number of subjects: 0
Study 1632394 — intervention group
Group type: EXPERIMENTAL
Intervention: Autodecremental pacing (10 ms decrement)
Number of subjects: 0
Study 1632394 — intervention group
Group type: COMPARATOR
Intervention: Pacing scheme using a 5 ms coupling decrement
Number of subjects: 0
Study 6594157 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemeprost vaginal pessaries
Number of subjects: 0
Study 6594157 — intervention group
Group type: COMPARATOR
Intervention: Extra-amniotic infusion of prostaglandin E2 (PGE2)
Number of subjects: 0
Study 3514164 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of prednisone daily for 2 weeks
Number of subjects: 16
Study 3514164 — intervention group
Group type: COMPARATOR
Intervention: Baseline spirometric data and beta‐agonist responsiveness
Number of subjects: 16
Study 3514164 — intervention group
Group type: COMPARATOR
Intervention: Previous studies of corticosteroids in COPD
Number of subjects: 16
Study 29744972 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 71
Study 27874299 — intervention group
Group type: EXPERIMENTAL
Intervention: TACO (immersion in 151 L of 2.1°C ± 0.8°C water)
Number of subjects: 16
Study 27874299 — intervention group
Group type: COMPARATOR
Intervention: CON (no immersion)
Number of subjects: 16
Study 27874299 — intervention group
Group type: EXPERIMENTAL
Intervention: TACO
Number of subjects: 16
Study 27874299 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 16